Who / What
Omalizumab is a monoclonal antibody medication, marketed under the name Xolair among others. It is an injectable treatment used for severe allergic conditions. It targets immunoglobulin E (IgE), a key component in allergic reactions.
Background & History
The provided data does not contain information about the origin, founding, or historical context of Omalizumab as an organization. It describes the medication itself and its function. Therefore, this section cannot be populated with information from the source.
Why Notable
Omalizumab is notable for its use in treating severe allergic conditions like asthma, nasal polyps, hives (urticaria), and IgE-mediated food allergies. It represents a targeted therapeutic approach to managing these conditions by specifically binding to IgE. The drug's development has significantly impacted the treatment of severe allergies, offering an alternative for patients who haven't responded to other therapies.
In the News
The provided data mentions that studies are underway regarding the increased risk of cardiovascular (CV) or cerebrovascular (CBV) disease in patients taking Omalizumab. This ongoing research highlights a current area of focus and potential concern related to the medication's long-term effects.
